Helixgate https://validator.w3.org/feed/docs/rss2.html HELIX AI Model Accurately Predicts RNA Splicing, Unlocks Precision Medicine STAT+: Pioneering trial for treating genetic disease before birth nears reality I&I biotech cAMPfield attracts top-tier investors in $180M Series A The next big pharma company will come from China Lilly and Engage Bio tie the knot with $202M acquisition Opinion: I saw Ebola as both doctor and patient. I wish people cared more about the Africans I worked alongside STAT+: Kennedy fires two leaders on preventive services task force Standardizing Cell Therapy Production With Technology Facelift Bristol Myers deepens AI investment with Anthropic deal FDA sends warning letter after Chinese supplier breaks GLP-1 import restrictions Pfizer’s next-gen pneumonia shot beats Prevnar 20; Relay targets $175M STAT+: Kennedy names interim surgeon general amid vacancies atop health department Pazdur declines to announce candidacy for vacated FDA commissioner role Fetal gene therapy’s progress calls into question the taboo on embryo editing Moderna’s stock rides hantavirus fears as spotlight returns to infectious disease platform There’s a leadership vacuum at NIH, too Beam one-ups Wave as both show promise of editing for AATD Beam one-ups Wave as both show promise of genetic editing for AATD AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis After Rubio’s critique, WHO defends work on Ebola response FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum Parabilis reveals IPO plans the day after Regeneron deal as listings heat up STAT+: Senate Democrats propose adding long-term care benefit to Medicare NIH behind in filling top roles, with 15 of 27 institutes led by acting directors Daiichi emerges from bruising 2 years with vision for cracking cancer’s big leagues J&J’s Duato makes 358 times his median employee; Vertex CEO makes just 80 times Regeneron, Parabilis Ink Up-to-$2.3B Antibody-Peptide Conjugate Collaboration STAT+: 23andMe offers to connect users’ DNA data with medical records STAT+: Marc Tessier-Lavigne addresses new book’s allegations about his conduct in Stanford misconduct case Oncogenic Signaling Shaped by a Golgi Trafficking Protein Pair Trump’s cuts to foreign aid are undermining the Ebola response, insiders say STAT+: Virginia governor vetoes legislation to create an advisory panel to lower the cost of prescription drugs How Gut Bacteria Apply Reversible Epigenetic “Bet-Hedging” Strategy to Adapt to Change TrumpRx adds hundreds of generic medicines to site Acceleron leaders and Westlake jumpstart new IPF biotech Google DeepMind and Edison Are Building the AI Scientist STAT+: Canadian medical societies lack sufficient conflict-of-interest policies, study finds STAT+: At a time of tumult at FDA, a former commissioner is hopeful it’s on a better path BioMarin drug acquired in buyout misses goal in rare disease study The state of consumer health Relay doubles the bar, outpacing Novartis with a 60% response in rare disease Takeda cuts send layoffs soaring in May, rising year over year Full-Life Technologies raises $150M; Quince’s reboot with pulmonary drug STAT+: Dexcom CEO hints at future uses for CGM Advances in genomics for drug discovery  STAT+: A new ranking of pharma companies by R&D performance  Nourish raises $100M for virtual nutrition care STAT+: Eli Lilly tops prominent rankings on pharma R&D performance BioMarin suffers another blow to rare disease portfolio in Phase 3 flop Home